MEREO BIOPHARMA GROUP PLC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MEREO BIOPHARMA GROUP PLC stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $6.00K.
- MEREO BIOPHARMA GROUP PLC stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $2.00K.
- MEREO BIOPHARMA GROUP PLC stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $280.00K.
- MEREO BIOPHARMA GROUP PLC stock issued during period, value, stock options exercised for fiscal 2025 was $39.00K, a 387.50% increase from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC stock issued during period, value, stock options exercised for fiscal 2024 was $8.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $39.00K 10-K · filed 2026-03-19 | |
| 2024-12-31 | $8.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $6.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $2.00K 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $280.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |